Immupharma Regulatory News (IMM)

ImmuPharma PLC (LSE:IMM)

("ImmuPharma" or the "Company")

ANNUAL GENERAL MEETING: 2012

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, held its AGM earlier today and is pleased to announce that all resolutions were duly passed.

Following the formal proceedings Dimitri Dimitriou Chief Executive Officer made the following statement:

"2011 was an important year for ImmuPharma. We regained the rights to our lead compound, LupuzorTM, from Cephalon Inc., at an exciting stage in its development following their acquisition by Teva Pharmaceuticals. Substantial progress had been made with LupuzorTM with the approval from the US Food and Drug Administration to start a Phase III trial with a Special Protocol Assessment as well as obtaining Fast Track designation potentially shortening the approval time by a year. 

"ImmuPharma is in detailed discussions with potential partners to re-license LupuzorTM while also exploring opportunities to retaining the rights until commercialisation.

"Our cancer programme, IPP-204106, has also made encouraging progress with promising early results in its Phase I/IIa trial. The trial is now completed and the data are being analysed and as previously announced 21% of patients demonstrated disease stabilisation for more than 6 months. The clinical development programme continues to be a key priority for ImmuPharma during 2012 with further clinical trials planned this year.

"Our key objectives for 2012 are to advance both LupuzorTM and our cancer programme and to continue to develop the rest of our asset base whilst continuing to carefully manage our cost base.

"In closing the Board would like to thank its shareholders for their continued support as well as its scientific advisors and the Centre Nationale de la Recherche Scientifique in France for their collaboration."

For further information please contact: